After years of advocates and experts demanding that jail facilities properly care for inmates suffering from addiction, the harrowing, dangerous experience of withdrawal in a cell may finally be an inhumane punishment of the past. With the Department of Justice enforcing the right of the incarcerated to all approved treatments and funding from the recent opioid settlement funds, the Allegheny County Jail is finally offering the full withdrawal management that the incarcerated has long needed?
Medications for opioid use disorder (MOUD) like methadone, buprenorphine, and naltrexone have been found to reduce mortality rates by up to 50%. Without them, inmates can suffer weeks of withdrawal, and face a much higher chance of overdose upon release. Forcing people not yet convicted of a crime to suffer through withdrawal — while withholding medications that could not just help them endure but could put them on the path to healing — is the opposite of rehabilitation.
Much of this progress stems from the aggressive efforts of the Biden administration’s Justice Department, culminating in a consent decree signed by the Allegheny County Jail last November. The settlement affirms that refusing to provide all approved MOUD options to inmates violates the Americans with Disabilities Act.
ACJ will for the first time implement MOUD induction — not just continuation — for incarcerated people in its care. This means that people with OUD can embark on a treatment path even if they weren’t on one prior to arrest.
These are all positive developments, but ACJ will still face an uphill battle in developing effective addiction treatment. The jail has a long history of losing staff, especially its medical professionals. Earlier this May, ACJ reported nearly 100 health worker job openings — a staggering 57.2% vacancy rate, currently only stemmed through temporary contract workers.
The ACJ settlement put other counties on notice that they could be liable if they continue to withhold these life-preserving medications. Butler County will use roughly $230,000 to implement medication protocols in its jail, while Beaver has indicated plans to spend $170,000 and Westmoreland $210,000.
It’s a massive upgrade from two years ago, when a study from the Pennsylvania Institutional Law Project found that over half of the commonwealth’s jails offer only naltrexone, a treatment that doesn’t curb withdrawal symptoms. Only 6% of jails allowed people not already on a treatment plan to begin one.
One cause for concern: The plans submitted by Western Pennsylvania counties to the state’s opioid settlement trust indicate MAT, or medication-assisted treatment, as opposed to MOUD. MAT uses medication only as part of a broader treatment strategy, including other interventions such as counseling. There’s nothing wrong with MAT, but medication alone — that is, MOUD — is proven to be effective. Counties should consider implementing MOUD programs, and not just MAT ones.
But progress is progress: Jail addiction care is one of the best uses of opioid settlement funds. Helping inmates through the crisis of withdrawal, and putting them on a path to recovery, is money well spent — both for them and for the society to which they will return.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.